Merck KGaA’s cancer portfolio helped drive overall healthcare sales growth in the third quarter as the major highlighted new collaboration agreements and clinical trial results that bode well for its oncology outlook.
The company’s total healthcare sales rose organically by 8.7% to €2.09bn in the third quarter. The sales beat analyst consensus estimates of approximately €2.02m and were pushed by oncology franchise sales, which increased by 24.5% to €453m in the third quarter
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?